BioSpace News Archive

The Board of Directors of Amedisys, Inc. announced a leadership change that President and Chief Executive Officer, Chris Gerard, will leave the company effective November 17, 2022, and Paul Kusserow, Chair of the Board of Directors will take over as Chief Executive Officer until a new Chief Executive Officer is identified.

Biofidelity, a revolutionary genomic technology company, has expanded its Board of Directors to include Matt Franklin, MBA, who will join as a Non-Executive Director effective immediately.

PTC Therapeutics, Inc. today announced that Upstaza™ (eladocagene exuparvovec) was granted authorization by the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain.

Agenus (Nasdaq: AGEN), an immuno-oncology company with a broad pipeline targeting cancer and infectious disease, announced expanded data from the Company’s Phase 1 study of botensilimab (Fc-enhanced anti-CTLA-4) and balstilimab (anti-PD-1) in patients with advanced sarcoma.

ABVC BioPharma, Inc. today announced that the Vitargus® Phase II Clinical Study Protocol has been approved by the Thailand Food and Drug Administration (FDA).

Nova Mentis Life Science Corp. (CSE: NOVA) (OTCQB: NMLSF) (FSE: HN3Q) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that it has entered into a research services agreement with KGK Sciences Inc. (KGK)

Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing proprietary, synthetic cannabinoid derivatives, has submitted an Investigational New Drug application (“IND”) to the U.S. Food and Drug Administration for SBI-100 Ophthalmic Emulsion (“SBI-100 OE), which it is developing for the treatment of glaucoma.

MiNK Therapeutics, Inc. announced that Dr. Jennifer Buell, President and CEO of MiNK, will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Thursday December 1st, at 4:45 PM ET.

Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for the quarter ended September 30, 2022 and provided a corporate update.

Abbott (NYSE: ABT) has been recognized by the Consumer Technology Association (CTA) with three CES 2023 Innovation Awards for its life-changing technologies that are advancing the health tech industry and improving the lives of people worldwide.